The drug development world has evolved a set of generally agreed upon steps for advancing potential targets forward. This is in part because the end goal - FDA approval and commercial viability drive the requirements and processes. The identification of clinically useful biomarkers is often an outcome of basic research into a biologic process that tangentially is recognized to have clinical utility. Validation processes are not standardized, and face cost barriers. However, one wonders if a move towards general agreement on processes, OR funding opportunities directed at validation of a select group of high potential markers might allow for greater impact and faster progress.